Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
Robert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; 3Clinic...
Guardado en:
Autores principales: | Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2c960f49b0f844b0a10151a59a239b6a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu R, et al.
Publicado: (2020) -
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Haowei (Linda) Sun, et al.
Publicado: (2021) -
Recent Advances in the Treatment of Hemophilia: A Review
por: Marchesini E, et al.
Publicado: (2021) -
Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
por: Mairead O’Donovan, et al.
Publicado: (2021) -
Sports and Children with Hemophilia: Current Trends
por: Lorenzo Moretti, et al.
Publicado: (2021)